< Terug naar vorige pagina

Publicatie

Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (vol 38, pg 1071, 2018)

Tijdschriftbijdrage - Tijdschriftartikel

Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests.
Tijdschrift: Clinical Drug Investigation
ISSN: 1173-2563
Issue: 1
Volume: 39
Pagina's: 113 - 113
Jaar van publicatie:2019